# US 2026/0193272 A1 · Selenium containing heterocycle compounds and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0193272 A1
- Document ID: US20260193272A1
- Status: Published application
- Kind: A1
- Application number: 19/132,870
- Filed: 2023-11-24
- Published: 2026-07-09
- Earliest claimed: 2022-11-24
- Assignees: Helios Huaming Biopharma Co., Ltd.
- Applicants: Helios Huaming Biopharma Co., Ltd.
- Inventors: Yanming WANG; Zhengwei GUO; Yanfei XIN; Mingde XIA
- Web page: https://patentgrep.com/patent/US20260193272A1

## CPC

- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C07D 517/04: Ortho-condensed systems
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07D 293/06: Selenazoles; Hydrogenated selenazoles
- C07D 517/00: Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A series of selenium containing heterocycle compounds, its pharmaceutically acceptable salt, stereoisomer or solvate are provided. A pharmaceutical composition including the compound, and use of the compound as PAD inhibitors, especially PAD4 inhibitors, are also provided. The selenium containing heterocycle compounds exhibit greatly improved enzymatic PAD4 inhibition activities and/or cellular PAD4 inhibition activities and/or cellular citrullination inhibitory activity and/or cellular NET formation inhibitory activity over the oxygen or sulfur containing compounds.

## Claims

### Claim 1

A compound of Formula (I), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a solvate thereof,
wherein,
one of A and B is Se, and the other one is N or CH;
E is N or CR6;
K is C or N;
F and G are independently selected from the group consisting of N, NR7, and CR7; R7 is selected from the group consisting of hydrogen and C1-C8 alkyl;
Ring Q is 4- to 15-membered heterocyclyl optionally substituted with 1-4 R4;
the dashed lines denote an optionally existing double bond, wherein a five-membered ring containing A and B is a first heteroaryl ring, and a five-membered ring containing F, G, and H is a second heteroaryl ring;
r, at each occurrence, is independently selected from 0, 1, 2, 3, and 4;
R1 and R2 are independently selected from the group consisting of H, F, Cl, Br, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkoxy, C1-C8 haloalkyl, C1-C8 alkylamino, C3-C8 cycloalkyl, C3-C9 heterocyclyl, C6-C10 aryl, and C5-C10 heteroaryl; R1 and R2 are optionally substituted with 0-5 Rc, Rc at each occurrence is independently selected from the group consisting of F, Cl, Br, —CN, —NO2, —OH, —NH2, C1-C8 alkyl, C1-C8 alkoxy, and C1-C8 haloalkyl;
R3, R5, and R6 are independently selected from the group consisting of H, F, Cl, Br, C1-C4 alkyl, and C1-C4 alkoxy;
R4 is selected from the group consisting of H, F, Cl, Br, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, —(CH2)pNRaRa, and —(CH2)pORb, optionally two R4 groups are taken together to form a carbocyclyl or heterocyclyl;
Ra and Rb, at each occurrence, is independently selected from H and C1-C4 alkyl;
p, at each occurrence, is independently selected from 0, 1, and 2.

### Claim 2 (depends on 1)

The compound according to claim 1, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, wherein the compound has Formula (IIa) or (IIb):
wherein when the compound has the Formula (IIa), A is N or CH; when the compound has the Formula (IIb), B is N or CH;
Ring Q is 4- to 12-membered heterocyclyl, preferably 4- to 7-membered monoheterocyclyl, 7- to 12-membered spiro heterocyclyl, or 6- to 10-membered bridged heterocyclyl; which-Ring Q is optionally substituted with 1-4 R4, wherein R4 is selected from the group consisting of H, F, Cl, Br, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, —(CH2)pNRaRa, and —(CH2)pORb;
E, F, G, K, R1, R2, R3, R4, R5, R6, R7, Ra, Rb, Rc, r, and p have the meanings as defined in claim 1.

### Claim 3 (depends on 1)

The compound according to claim 1, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, wherein the compound has Formula (IIIa) or (IIIb):
wherein when the compound has the Formula (IIIa), A is N or CH; when the compound has the Formula (IIIb), B is N or CH;
Ring Q is 4- to 12-membered heterocyclyl, preferably 4- to 7-membered monoheterocyclyl, 7- to 12-membered spiro heterocyclyl, or 6- to 10-membered bridged heterocyclyl; Ring Q is optionally substituted with 1-4 R4, wherein R4 is selected from the group consisting of H, F, Cl, Br, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, —(CH2)pNRaRa, and —(CH2)pORb;
E, F, G, K, R1, R2, R3, R4, R5, R6, R7, Ra, Rb, Rc, r, and p have the meanings as defined in claim 1.

### Claim 4 (depends on 1)

The compound according to claim 1, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, wherein
B is Se;
A is N or CH;
a bicyclic ring containing E, F, G, and K is selected from the group consisting of the following structures:
R1, R2, R3, R4, R5, R6, R7, Ra, Rb, Rc, r, and p have the meanings as defined in claim 1.

### Claim 5 (depends on 1)

The compound according to claim 1, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof,
wherein Ring Q is selected from the group consisting of:
Ring Q is optionally substituted with 1-4 R4, wherein R4 is selected from the group consisting of H, F, Cl, Br, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, —(CH2)pNRaRa, and —(CH2)pORb;
Ra, Rb, and p have the meanings as defined in claim 1.

### Claim 6 (depends on 1)

The compound according to claim 1, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, wherein the compound has Formula (IVa) or (IVb):
wherein when the compound has the Formula (IVa), A is N or CH; when the compound has the Formula (IVb), B is N or CH;
Ring Q with R4 substitution is selected from the group consisting of
wherein R4 in
is selected from the group consisting of H, F, Cl, Br, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, —(CH2)pNRaRa, and —(CH2)pORb;
R1, R2, R3, R4, R5, R6, R7, Ra, Rb, Rc, r, and p have the meanings as defined in claim 1.

### Claim 7 (depends on 1)

The compound according to claim 1, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, wherein the compound has Formula (IVa) or (IVb):
wherein when the compound has the Formula (IVa), A is N or CH; when the compound has the Formula (IVb), B is N or CH;
Ring Q with R4 substitution is selected from the group consisting of
R1 is selected from the group consisting of H, C1-C8 alkyl substituted with 0-5 Rc, C3-C6 cycloalkyl substituted with 0-5 Rc, C6-C10 aryl substituted with 0-5 Rc, and C5-C10 heteroaryl substituted with 0-4 Rc;
R2 is selected from the group consisting of H, C1-C8 alkyl substituted with 0-5 Rc, C3-C6 cycloalkyl substituted with 0-5 Rc, C5-C9 heterocycloalkyl substituted with 0-5 Rc, C6-C10 aryl substituted with 0-5 Rc, and C5-C10 heteroaryl substituted with 0-4 Rc;
R3 is selected from the group consisting of H, F, Cl, Br, C1-C4 alkyl, and C1-C4 alkoxy, and is preferably H, F, or C1-C3 alkoxy;
R5 and R6 are independently selected from the group consisting of H, F, Cl, Br, C1-C4 alkyl, and C1-C4 alkoxy, and are preferably H, F, or C1-C3 alkyl;
R7 is selected from the group consisting of hydrogen and C1-C8 alkyl, and is preferably H or C1-C3 alkyl;
Rc at each occurrence is independently selected from the group consisting of F, Cl, Br, —CN, —NO2, —OH, —NH2, C1-C3 alkyl, C1-C3 alkoxy, and C1-C3 haloalkyl;
r is 1 or 2.

### Claim 8 (depends on 1)

The compound according to claim 1, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, wherein
R1 is selected from cyclopropyl substituted with 0-2 Rc, cyclobutyl substituted with 0-2 Rc, methyl, tert-butyl, phenyl substituted with 0-2 Rc, furanyl substituted with 0-2 Rc, thienyl substituted with 0-2 Rc, pyridinyl substituted with 0-2 Rc;
R2 is selected from H, F, Cl, Br, methyl, ethyl, cyclopropyl substituted with 0-2 Rc, phenyl substituted with 0-2 Rc, pyrrolidinyl substituted with 0-2 Rc, pyridinyl substituted with 0-2 Rc, piperidinyl substituted with 0-2 Rc;
Rc at each occurrence is independently selected from the group consisting of F, C1-C3 alkyl, C1-C3 alkoxy, and C1-C3 haloalkyl, and is preferably methyl, —OMe, or —CF3;
r is 1.

### Claim 9 (depends on 1)

The compound according to claim 1, the pharmaceutically acceptable salt thereof the stereoisomer thereof, or the solvate thereof, wherein the compound is selected from the group consisting of:

### Claim 10

A compound of formula (V), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a solvate thereof,
wherein,
Ring W is 4- to 15-membered heterocyclyl, preferably 4- to 7-membered monoheterocyclyl, more preferably 5- to 7-membered monoheterocyclyl, and Ring W is optionally substituted with 1-4 R14;
t, at each occurrence, is independently selected from 0, 1, 2, 3, and 4;
R8 and R9 are independently selected from the group consisting of H, F, Cl, Br, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkoxy, C1-C8 haloalkyl, C1-C8 alkylamino, C3-C8 cycloalkyl, C3-C9 heterocyclyl, C6-C10 aryl, and C5-C10 heteroaryl; R8 and R9 are optionally substituted with 0-5 Rc, Rc at each occurrence is independently selected from the group consisting of F, Cl, Br, —CN, —NO2, —OH, —NH2, C1-C8 alkyl, C1-C8 alkoxy, and C1-C8 haloalkyl;
R10, R12 and R13 are independently selected from the group consisting of H, F, Cl, Br, C1-C4 alkyl, and C1-C4 alkoxy;
R11 is selected from the group consisting of hydrogen and C1-C8 alkyl;
R14 is selected from the group consisting of H, F, Cl, Br, —CN, —NH2, —OH, —NO2, and C1-C4 alkyl;
Rd is independently selected from H and C1-C4 alkyl.

### Claim 11 (depends on 10)

The compound according to claim 10, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, wherein Ring W is 6-membered monoheterocyclyl, preferably piperidinyl, and Ring W is optionally substituted with 1 or 2 R14.

### Claim 12 (depends on 10)

The compound according to claim 10, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, wherein
t is 1 or 2;
R8 is selected from the group consisting of H, C1-C5 alkyl substituted with 0-5 Rc, C3-C6 cycloalkyl substituted with 0-5 Re, C6-C10 aryl substituted with 0-5 Rc, and C5-C10 heteroaryl substituted with 0-4 Rc;
R9 is selected from the group consisting of H, C1-C8 alkyl substituted with 0-5 Rc, C3-C6 cycloalkyl substituted with 0-5 Rc, C5-C9 heterocycloalkyl substituted with 0-5 Rc, C6-C10 aryl substituted with 0-5 Rc, and C5-C10 heteroaryl substituted with 0-4 Rc;
R10 is selected from the group consisting of H, F, Cl, Br, C1-C4 alkyl, and C1-C4 alkoxy, and is preferably H, F, or C1-C3 alkoxy;
R12 and R13 are independently selected from the group consisting of H, F, Cl, Br, C1-C4 alkyl, and C1-C4 alkoxy, and are preferably H, F, or C1-C3 alkyl;
R11 is selected from the group consisting of hydrogen and C1-C8 alkyl, and is preferably H or C1-C3 alkyl; and
Rc at each occurrence is independently selected from the group consisting of F, Cl, Br, —CN, —NO2, —OH, —NH2, C1-C3 alkyl, C1-C3 alkoxy, and C1-C3 haloalkyl.

### Claim 13 (depends on 10)

The compound according to claim 10, the pharmaceutically acceptable salt thereof the stereoisomer thereof, or the solvate thereof,
wherein
R8 is selected from cyclopropyl substituted with 0-2 Rc, cyclobutyl substituted with 0-2 Rc, methyl, tert-butyl, phenyl substituted with 0-2 Rc, furanyl substituted with 0-2 Rc, thienyl substituted with 0-2 Rc, pyridinyl substituted with 0-2 Rc;
R9 is selected from H, F, Cl, Br, methyl, ethyl, cyclopropyl substituted with 0-2 Rc, phenyl substituted with 0-2 Rc, pyrrolidinyl substituted with 0-2 Rc, pyridinyl substituted with 0-2 Rc, piperidinyl substituted with 0-2 Rc;
Rc at each occurrence is independently selected from the group consisting of F, C1-C3 alkyl, C1-C3 alkoxy, and C1-C3 haloalkyl, and is preferably methyl, —OMe, or —CF3;
Rd is H; and
t is 1.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, and one or more pharmaceutically acceptable carriers.

### Claim 16 (depends on 1)

A method of treating a PAD4-mediated or NET-mediated disease, disorder, or condition in a subject, comprising administering to the subject a therapeutically effective amount of the compound according to claim 1, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, wherein the PAD4-mediated or NET-mediated disease, disorder, or condition is selected from the group consisting of cancers, rheumatoid arthritis, multiple sclerosis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cystic fibrosis, asthma, cutaneous lupus erythematosis, psoriasis, Alzheimer's disease, ischemia-reperfusion injury, and immune responses induced during transplant rejection.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the PAD4-mediated or NET-mediated disease, disorder, or condition is selected from the group consisting of lung cancer, liver cancer, blood cancer, esophageal cancer, breast cancer, and colon cancer.

### Claim 18 (depends on 1)

A combination therapy, comprising administering to a subject a first therapeutic agent and one or more additional therapeutics, wherein the first therapeutic agent comprises the compound according to claim 1, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, the one or more additional therapeutics is selected from the group consisting of radiotherapy, chemotherapy, cell therapy, and immune checkpoint inhibitor, wherein the cell therapy comprises CAR-T, CAR-NK, CAR-NKT, CAR-M, CAR-Treg, CAR-γδT, TIL, and TCR-T, the immune checkpoint inhibitor comprises PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, B7-H3 inhibitor, LAG3 inhibitor, TIM3 inhibitor, TIGIT inhibitor, anti-PDL1/TGFβ bispecific antibody, anti-EpCAM-CD3 bispecific antibody, and/or CD40 agonists.

### Claim 19 (depends on 18)

The combination therapy according to claim 18, wherein the first therapeutic agent and the one or more additional therapeutics are administered together, simultaneously, sequentially, or alternately; and
the first therapeutic agent and the one or more additional therapeutics are administrated in a lower dose in comparison with a dose of the first therapeutic agent or the one or more additional therapeutics when administered alone.

### Claim 20

(canceled)

### Claim 21

A method for preparing selenazole compound S-4, comprising the following steps:
reacting a nitrile compound S-1 with CO and Se powder to yield a compound S-2, which is further reacted with a compound S-3 to yield the selenazole compound S-4, wherein,
R15 is selected from the group consisting of H, F, Cl, Br, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkoxy, C1-C8 haloalkyl, C1-C8 alkylamino, C3-C8 cycloalkyl, C3-C9 heterocyclyl, C6-C10 aryl, and C5-C10 heteroaryl; R15 is optionally substituted with 0-5 Rc, Rc at each occurrence is independently selected from the group consisting of F, Cl, Br, —CN, —NO2, —OH, —NH2, C1-C8 alkyl, C1-C8 alkoxy, and C1-C8 haloalkyl; and is preferably selected from the group consisting of H, C1-C5 alkyl substituted with 0-5 Rc, C3-C6 cycloalkyl substituted with 0-5 Rc, C6-C10 aryl substituted with 0-5 Rc, and C5-C10 heteroaryl substituted with 0-4 Rc; and is more preferably selected from the group consisting of cyclopropyl substituted with 0-2 Rc, cyclobutyl substituted with 0-2 Rc, methyl, tert-butyl, phenyl substituted with 0-2 Rc, furanyl substituted with 0-2 Rc, thienyl substituted with 0-2 Rc, and pyridinyl substituted with 0-2 Rc;
Rc is at each occurrence is independently selected from the group consisting of F, C1-C3 alkyl, C1-C3 alkoxy, and C1-C3 haloalkyl, and is preferably methyl, —OMe, or —CF3;
R16 is CHO.

### Claim 22

(canceled)

### Claim 23 (depends on 10)

A pharmaceutical composition comprising the compound according to claim 10, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, and one or more pharmaceutically acceptable carriers.

### Claim 24 (depends on 10)

A method of treating a PAD4-mediated or NET-mediated disease, disorder, or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of the compound according to claim 10, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, wherein the PAD4-mediated or NET-mediated disease, disorder, or condition is selected from the group consisting of cancers, rheumatoid arthritis, multiple sclerosis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cystic fibrosis, asthma, cutaneous lupus erythematosis, psoriasis, Alzheimer's disease, ischemia-reperfusion injury, and immune responses induced during transplant rejection.

### Claim 25 (depends on 10)

A combination therapy, comprising administering to a subject a first therapeutic agent and one or more additional therapeutics, wherein the first therapeutic agent comprises the compound according to claim 10, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, or the solvate thereof, the one or more additional therapeutics is selected from the group consisting of radiotherapy, chemotherapy, cell therapy, and immune checkpoint inhibitor, wherein the cell therapy comprises CAR-T, CAR-NK, CAR-NKT, CAR-M, CAR-Treg, CAR-γδT, TIL, and TCR-T, the immune checkpoint inhibitor comprises PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, B7-H3 inhibitor, LAG3 inhibitor, TIM3 inhibitor, TIGIT inhibitor, anti-PDL1/TGFβ bispecific antibody, anti-EpCAM-CD3 bispecific antibody, and/or CD40 agonists.
